R. Gralla, S. Bošnjak, A. Hontsa
Mar 14, 2014
Citations
13
Influential Citations
140
Citations
Quality indicators
Journal
Annals of Oncology
Abstract
In this multinational, phase III study, the safety and efficacy of NEPA, a convenient, fixed-dose antiemetic combination of netupitant, a highly selective NK1 receptor antagonist (RA), and palonosetron, a distinct 5-HT3 RA, were evaluated over multiple cycles of highly and moderately emetogenic chemotherapy. NEPA was shown to be safe, well tolerated and highly effective over 1961 chemotherapy cycles.